Hemostemix Announces $2,725,982 Update to Second Closing
Calgary, Alberta--(Newsfile Corp. - December 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is amending its closing documents to include an additional subscription of $50,000. The combined Offerings resulted in gross proceeds of $2,725,981.77 upon the issuance of 54,519,635 Units. The Offering is subject to all necessary regulatory approvals including acceptance from the Exchange. All securities issued in...
2024-12-03 4:41 PM EST
Hemostemix Announces $2,675,981 Private Placement Including Second Tranche of $833,258
Calgary, Alberta--(Newsfile Corp. - November 28, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed its second and final tranche of the private placement of units ("Units"), as announced on October 11, 2024, for gross proceeds of $833,258 (the "Offering"). The Offering consisted of the issuance of an aggregate of 16,665,160 Units at a price of $0.05 per Unit. Each Unit consists of one common share in the...
2024-11-28 5:42 PM EST
Hemostemix Announces ACP-01 Treatment-Purchase Available with Social Media Campaign Underway
Calgary, Alberta--(Newsfile Corp. - November 25, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that, focusing on revenue, it has retained social media experts to educate and sell caregivers and individuals suffering from Chronic Limb Threatening Ischemia ("CLTI"), Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy, and Congestive Heart Failure, an ACP-01 treatment, available under special access programs. ACP-01...
2024-11-25 1:43 PM EST
Hemostemix Announces the First Tranche Closing of $1.8M of Its Recently Announced Private Placement
Calgary, Alberta--(Newsfile Corp. - October 31, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed its first tranche of the private placement of units ("Units"), as announced on October 11, 2024, for gross proceeds of $1,842,723 (the "Offering"). The Offering consisted of the issuance of an aggregate of 36,854,475 Units at a price of $0.05 per Unit. Each Unit consists of one common share in the capital of the...
2024-10-31 4:04 PM EDT
Hemostemix's Private Placement
Calgary, Alberta--(Newsfile Corp. - October 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $4,000,000 of financing in tranches from the sale of Common Shares and Units at $0.05 each. Each Unit shall consist of one Common Share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each Warrant entitling the holder to acquire one Common Share at a price of $0.12 per...
2024-10-11 8:29 AM EDT
Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01
Calgary, Alberta--(Newsfile Corp. - August 1, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it and CytoImmune Therapuetics ("CytoImmune") today signed a binding and funded definitive Manufacturing Services Agreement that re-establishes production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manufacturing facility in Toa Baja, Puerto Rico.
2024-08-01 10:03 PM EDT
Hemostemix Announces Trademark Granted by Switzerland and Interest Payment
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by the Swiss Trademark Office. "In four heart and three chronic limb threatening ischemia (CLTI) trials, including one retrospective study of 54 patients, ACP-01 is demonstrated to be safe and statistically efficacious as a treatment of...
2024-06-11 11:06 AM EDT
Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it has signed a Letter of Intent ("LOI") with CytoImmune Therapuetics ("CytoImmune") to re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manufacturing facility. The Company is also pleased to announce that it has received commitments for $1,800,000 of Units in a non-brokered private placement as more fully described below.
2024-06-03 9:05 AM EDT
Hemostemix Announces Engagement of Oak Hill Asset Management Inc.
Calgary, Alberta--(Newsfile Corp. - March 7, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. ("OHAM"), an Exempt Market Dealer to provide capital markets advice related to the Company's capital markets strategy. Services include advice on the structure of equity or debt capital financing and the identification of potential future investors. The Company intends...
2024-03-07 4:01 PM EST
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences
Calgary, Alberta--(Newsfile Corp. - February 6, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Journal of Biomedical Research and Environmental Sciences published the Company's Phase II randomized clinical trial results today. The publication highlights the results of no option critical limb ischemia patients who started the clinical trial with an ulcer, comparing wound healing, amputation, and mortality between the...
2024-02-06 10:08 AM EST
Hemostemix Clarifies its October 3, 2023 News Release
Calgary, Alberta--(Newsfile Corp. - December 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to like to clarify its press release of October 3, 2023. It refered to the private placement of $320,125. The Company closed the financing in the amount of $320,385 with the issuance of 2,669,875 units. In connection with that Offering, the Corporation paid eligible finders aggregate fees of $5,750.40 in cash and issued 47,920 finder...
2023-12-29 4:02 PM EST
Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease
Calgary, Alberta--(Newsfile Corp. - October 30, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that Stem Cell Research & Therapy published the Company's seventh peer reviewed study of ACP-01 - the third peer reviewed study of ACP-01 as a treatment for heart disease (ischemic and non-ischemic dilated cardiomyopathy), which demonstrates ACP-01 regenerates and improves cardiac function by up to 24.1% at 12 months in ischemic cardiomyopathy, and regenerates...
2023-10-30 2:16 PM EDT
Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000
Calgary, Alberta--(Newsfile Corp. - October 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it has amended its $2.5 million 5 year convertible debenture, which originally closed on June 11, 2021 ("CD1") resulting in an expected interest saving of $569,868. The 4 material amendments are summarized as follows: 1) Interest will be amended from 6% per annum to nil (zero) from January 1, 2023 to maturity (June 11, 2026) saving the Company up to $569,868 of...
2023-10-23 10:03 AM EDT
Hemostemix Closed $320,125 Private Placement
Calgary, Alberta--(Newsfile Corp. - October 3, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it closed its private placement of $320,125, the sale of approximately 2.66 Million Units priced at $0.12 each. Each Unit sold consisted of one common share in the capital of the Company ("Common Share") and one half of one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.25 per...
2023-10-03 10:55 AM EDT
Hemostemix Announces Private Placement
Calgary, Alberta--(Newsfile Corp. - September 27, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a new private placement of $325,125, the sale of approximately 2.7 Million Units priced at $0.12 each. Each Unit shall consist of one common share in the capital of the Company ("Common Share") and one half of one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.25 per Common...
2023-09-27 5:10 PM EDT
Hemostemix Announces New Publication: How NCP-01 Supports Brain Computer Interfaces
Calgary, Alberta--(Newsfile Corp. - September 12, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce its study of NCP-01 supporting brain computer interfaces has been submitted for peer review publication. Mitigating Challenges Facing Clinical Applications of Implantable Biosensors Supporting Brain Computer Interfaces is co-authored by Dr. Chris McNorgan, Dr. Fraser C. Henderson, Sr., Dr. Ina Sarel, Dr. Ken Webb and Dr. Jeong Soo Lee. Within the last two...
2023-09-12 9:15 AM EDT
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications
Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it incorporated Hemostemix Quebec Inc. and has applied for grant funding of $6 Million, to locate production of ACP-01 in Montreal. "We are moving production of ACP-01 to Quebec, as have negotitated terms for a possible shared site where we can co-locate our staff to produce a treatment for clinical trials at 1/10th the cost of contract manufacturers," stated...
2023-08-29 1:58 PM EDT
Hemostemix Announces Arbitration Award of CAD $315,684 Plus Private Placement
Calgary, Alberta--(Newsfile Corp. - August 14, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that on August 10, 2023 it received a final cost award from the International Center for Dispute Resolution (ICDR), International Abritration Tribunal, in the Matter of Arbitration between Elmar Burchardt vs Hemostemix Inc. The award stipulates Dr. Burchardt is to pay Hemostemix Inc. CAD $315,684 of its costs. Certified, for the purposes of Article I of the New...
2023-08-14 9:06 AM EDT
Hemostemix Submits Its Retrospective Heart Study to Leading Stem Cell Journal and Has Prepared Its CLI Phase II Clinical Trial Manuscript for Peer Review
Calgary, Alberta--(Newsfile Corp. - August 8, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it submitted for publication its retrospective cardiomyopathy study to a leading stem cell journal. The study, Safety and Outcomes Analysis: Transcatheter Implantation of Autologous Angiogenic Cell Precursors for Treatment of Cardiomyopathy, was co-authored by Jane R. Schubart PhD, Amirhossein Zare MD, Roberto M. Fernandez-de-Castro MD, MSc, Hector Rosario...
2023-08-08 11:45 AM EDT
Hemostemix Closes $403,539 of the Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - June 28, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it has closed the sale of 3,362,833 Units at a subscription price of $0.12 per Unit for gross proceeds of $403,539.96. In connection with the Closing, the Corporation will pay finder fees ("Finder Fees") to one or more advisors, dealers or finders ("Finders") for their assistance in the Private Placement including: (a) a Finder's fee payable in cash not to exceed...
2023-06-28 8:56 AM EDT